Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


21.05.2018

1 Acta Cytol
4 Anticancer Res
2 BMC Cancer
3 Br J Cancer
1 Breast Cancer (Dove Med Press)
1 Breast Cancer Res
8 Breast Cancer Res Treat
1 Cancer Lett
3 Clin Breast Cancer
1 Curr Treat Options Oncol
2 Eur J Cancer
2 Eur J Surg Oncol
1 Eur Radiol
1 Gene
4 Int J Cancer
1 J Biol Chem
1 J Clin Oncol
1 J Pathol
1 NPJ Breast Cancer
3 Oncogene
5 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Acta Cytol

  1. NISHIMURA R, Murata Y, Mori K, Yamashiro K, et al
    Evaluation of the HER2 and Hormone Receptor Status in Metastatic Breast Cancer Using Cell Blocks: A Multi-Institutional Study.
    Acta Cytol. 2018 May 15:1-7. doi: 10.1159/000488382.
    PubMed     Text format     Abstract available


    Anticancer Res

  2. LIU LC, Wu YC, Kuo SC, Ho CT, et al
    2-Phenylnaphthyridin-4-one Derivative LYF-11 Inhibits Interleukin-6-mediated Epithelial-to-Mesenchymal Transition via the Inhibition of JAK2/STAT3 Signaling Pathway in MCF-7 Cells.
    Anticancer Res. 2018;38:2849-2859.
    PubMed     Text format     Abstract available

  3. OKARVI SM, Aljammaz I
    Preparation and In Vitro and In Vivo Characterization of the Tumor-specific Antigen-derived Peptide as a Potential Candidate for Targeting Human Epidermal Growth Factor Receptor 2-positive Breast Carcinomas.
    Anticancer Res. 2018;38:2823-2830.
    PubMed     Text format     Abstract available

  4. TATARA T, Mukohara T, Tanaka R, Shimono Y, et al
    3D Culture Represents Apoptosis Induced by Trastuzumab Better than 2D Monolayer Culture.
    Anticancer Res. 2018;38:2831-2839.
    PubMed     Text format     Abstract available

  5. LEHMANN-CHE J, Miquel C, Wong J, Callens C, et al
    First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma.
    Anticancer Res. 2018;38:2909-2914.
    PubMed     Text format     Abstract available


    BMC Cancer

  6. REYNOLDS KL, Bedard PL, Lee SH, Lin CC, et al
    A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
    BMC Cancer. 2017;17:646.
    PubMed     Text format     Abstract available

  7. BATES JP, Derakhshandeh R, Jones L, Webb TJ, et al
    Mechanisms of immune evasion in breast cancer.
    BMC Cancer. 2018;18:556.
    PubMed     Text format     Abstract available


    Br J Cancer

  8. MORTAZAVI SMJ
    Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study'.
    Br J Cancer. 2018 May 17. pii: 10.1038/s41416-018-0060.
    PubMed     Text format    

  9. GULLO G, Walsh N, Fennelly D, Bose R, et al
    Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project.
    Br J Cancer. 2018 May 18. pii: 10.1038/s41416-018-0114.
    PubMed     Text format     Abstract available

  10. JOHNS LE, Jones ME, Schoemaker MJ, McFadden E, et al
    Reply to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".
    Br J Cancer. 2018 May 17. pii: 10.1038/s41416-018-0092.
    PubMed     Text format    


    Breast Cancer (Dove Med Press)

  11. FORSYTHE A, Chandiwana D, Barth J, Thabane M, et al
    Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer.
    Breast Cancer (Dove Med Press). 2018;10:69-78.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  12. ALLOUCHERY V, Beaussire L, Perdrix A, Sefrioui D, et al
    Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients.
    Breast Cancer Res. 2018;20:40.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  13. O'LOUGHLIN M, Andreu X, Bianchi S, Chemielik E, et al
    Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study.
    Breast Cancer Res Treat. 2018 May 17. pii: 10.1007/s10549-018-4825.
    PubMed     Text format     Abstract available

  14. BLOK EJ, Engels CC, Dekker-Ensink G, Meershoek-Klein Kranenbarg E, et al
    Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer.
    Breast Cancer Res Treat. 2018 May 15. pii: 10.1007/s10549-018-4785.
    PubMed     Text format     Abstract available

  15. ONO H, Sowa Y, Horinaka M, Iizumi Y, et al
    The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
    Breast Cancer Res Treat. 2018 May 11. pii: 10.1007/s10549-018-4815.
    PubMed     Text format     Abstract available

  16. LU CY, Zhang F, Wagner AK, Nekhlyudov L, et al
    Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer.
    Breast Cancer Res Treat. 2018 May 12. pii: 10.1007/s10549-018-4821.
    PubMed     Text format     Abstract available

  17. LIN CH, Chuang PY, You SL, Chiang CJ, et al
    Effect of glucocorticoid use on survival in patients with stage I-III breast cancer.
    Breast Cancer Res Treat. 2018 May 14. pii: 10.1007/s10549-018-4787.
    PubMed     Text format     Abstract available

  18. KOTSOPOULOS J, Gronwald J, Lynch HT, Eisen A, et al
    Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2018 May 17. pii: 10.1007/s10549-018-4822.
    PubMed     Text format     Abstract available

  19. HOSTE G, Punie K, Wildiers H, Beuselinck B, et al
    Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer.
    Breast Cancer Res Treat. 2018 May 16. pii: 10.1007/s10549-018-4827.
    PubMed     Text format     Abstract available

  20. WILLIAMSON TJ, Love SM, Clague DeHart JN, Jorge-Miller A, et al
    Metastatic Breast Cancer Collateral Damage Project (MBCCD): Scale development and preliminary results of the Survey of Health, Impact, Needs, and Experiences (SHINE).
    Breast Cancer Res Treat. 2018 May 16. pii: 10.1007/s10549-018-4823.
    PubMed     Text format     Abstract available


    Cancer Lett

  21. YAN M, Wang Y, Wong CW, Mei-Yu Or P, et al
    PTEN PDZ-binding domain suppresses mammary carcinogenesis in the MMTV-PyMT breast cancer model.
    Cancer Lett. 2018 May 14. pii: S0304-3835(18)30337.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  22. KIM S, Moon BI, Lim W, Park S, et al
    Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers.
    Clin Breast Cancer. 2018 Mar 23. pii: S1526-8209(17)30736.
    PubMed     Text format     Abstract available

  23. QINGQING H, Jian Z, Dayong Z, Ziyi F, et al
    Robot-Assisted Internal Mammary Lymph Node Chain Dissection for Breast Cancer.
    Clin Breast Cancer. 2018 Apr 19. pii: S1526-8209(18)30134.
    PubMed     Text format    

  24. CHO WK, Choi DH, Park W, Cha H, et al
    Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment.
    Clin Breast Cancer. 2018 Apr 19. pii: S1526-8209(17)30765.
    PubMed     Text format     Abstract available


    Curr Treat Options Oncol

  25. JASRA S, Anampa J
    Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review.
    Curr Treat Options Oncol. 2018;19:30.
    PubMed     Text format     Abstract available


    Eur J Cancer

  26. ZAHL PH
    Letter comments on EJC published paper: 'No overdiagnosis in the Norwegian Breast Cancer Screening Program estimated by combining record linkage and questionnaire information in the Norwegian Women and Cancer study'.
    Eur J Cancer. 2018 May 11. pii: S0959-8049(18)30774.
    PubMed     Text format    

  27. LUND E, Nakamura A, Thalabard JC
    Re: No overdiagnosis in the Norwegian Breast Cancer Screening Program estimated by combining record linkage and questionnaire information in the Norwegian Women and Cancer Study.
    Eur J Cancer. 2018 May 11. pii: S0959-8049(18)30773.
    PubMed     Text format    


    Eur J Surg Oncol

  28. TASOULIS MK, Iqbal FM, Cawthorn S, MacNeill F, et al
    Reply to: Subcutaneous implant breast reconstruction: The importance of objectively assessing the outcomes.
    Eur J Surg Oncol. 2018;44:273.
    PubMed     Text format    

  29. ONESTI MG, Fanelli B, Di Taranto G
    Subcutaneous implant breast reconstruction: the importance of objectively assessing the outcomes.
    Eur J Surg Oncol. 2018;44:271-272.
    PubMed     Text format    


    Eur Radiol

  30. CHEN BB, Lu YS, Yu CW, Lin CH, et al
    Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancer.
    Eur Radiol. 2018 May 16. pii: 10.1007/s00330-018-5448.
    PubMed     Text format     Abstract available


    Gene

  31. BAGHI N, Bakhshinejad B, Keshavarz R, Babashah S, et al
    Dendrosomal nanocurcumin and exogenous p53 can act synergistically to elicit anticancer effects on breast cancer cells.
    Gene. 2018 May 10. pii: S0378-1119(18)30508-0. doi: 10.1016/j.gene.2018.
    PubMed     Text format     Abstract available


    Int J Cancer

  32. WU W, Chen F, Cui X, Yang L, et al
    LncRNA NKILA Suppresses TGF-beta-induced Epithelial-Mesenchymal Transition by Blocking NF-kappaB Signaling in Breast Cancer.
    Int J Cancer. 2018 May 15. doi: 10.1002/ijc.31605.
    PubMed     Text format     Abstract available

  33. LA MANNA S, Lee E, Ouzounova M, Di Natale C, et al
    Mimetics of Suppressor of cytokine signalling 3: novel potential therapeutics in triple breast cancer.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31594.
    PubMed     Text format     Abstract available

  34. TROISI R, Gulbech Ording A, Grotmol T, Glimelius I, et al
    Pregnancy Complications and Subsequent Breast Cancer Risk in the Mother: A Nordic population-based case-control study.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31600.
    PubMed     Text format     Abstract available

  35. LI J, Jing R, Wei H, Wang M, et al
    Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer.
    Int J Cancer. 2018 May 12. doi: 10.1002/ijc.31601.
    PubMed     Text format     Abstract available


    J Biol Chem

  36. YAN T, Zhang A, Shi F, Chang F, et al
    Integrin alphavbeta3-associated DAAM1 is essential for collagen-induced invadopodia extension and cell haptotaxis in breast cancer cells.
    J Biol Chem. 2018 May 11. pii: RA117.000327. doi: 10.1074/jbc.RA117.000327.
    PubMed     Text format     Abstract available


    J Clin Oncol

  37. WANG L, Hong BY, Kennedy SA, Chang Y, et al
    Predictors of Unemployment After Breast Cancer Surgery: A Systematic Review and Meta-Analysis of Observational Studies.
    J Clin Oncol. 2018 May 14:JCO2017773663. doi: 10.1200/JCO.2017.77.3663.
    PubMed     Text format     Abstract available


    J Pathol

  38. DE GROOT JS, Ratze MAK, van Amersfoort M, Eisemann T, et al
    alphaE-catenin is a candidate tumor suppressor for the development of E-cadherin expressing lobular-type breast cancer.
    J Pathol. 2018 May 17. doi: 10.1002/path.5099.
    PubMed     Text format     Abstract available


    NPJ Breast Cancer

  39. STOVER DG, Gil Del Alcazar CR, Brock J, Guo H, et al
    Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer.
    NPJ Breast Cancer. 2018;4:10.
    PubMed     Text format     Abstract available


    Oncogene

  40. TANG J, Li Y, Sang Y, Yu B, et al
    LncRNA PVT1 regulates triple-negative breast cancer through KLF5/beta-catenin signaling.
    Oncogene. 2018 May 15. pii: 10.1038/s41388-018-0310.
    PubMed     Text format     Abstract available

  41. WANG PS, Chou CH, Lin CH, Yao YC, et al
    A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer.
    Oncogene. 2018 May 14. pii: 10.1038/s41388-018-0293.
    PubMed     Text format     Abstract available

  42. GALA K, Li Q, Sinha A, Razavi P, et al
    KMT2C mediates the estrogen dependence of breast cancer through regulation of ERalpha enhancer function.
    Oncogene. 2018 May 14. pii: 10.1038/s41388-018-0273.
    PubMed     Text format     Abstract available


    PLoS One

  43. FATIMA I, El-Ayachi I, Taotao L, Angeles Lillo M, et al
    Correction: The natural compound Jatrophone interferes with Wnt/beta-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer.
    PLoS One. 2018;13:e0197796.
    PubMed     Text format     Abstract available

  44. ECKHARDT BL, Gagliardi M, Iles L, Evans K, et al
    Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies.
    PLoS One. 2018;13:e0195932.
    PubMed     Text format     Abstract available

  45. LIM ST, Park CH, Kim SY, Nam SJ, et al
    The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer.
    PLoS One. 2018;13:e0197523.
    PubMed     Text format     Abstract available

  46. ZENG Z, Jiang X, Li X, Wells A, et al
    Conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls.
    PLoS One. 2018;13:e0197064.
    PubMed     Text format     Abstract available

  47. KHARMAN-BIZ A, Gao H, Ghiasvand R, Haldosen LA, et al
    Expression of the three components of linear ubiquitin assembly complex in breast cancer.
    PLoS One. 2018;13:e0197183.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: